Our aim is to conclusively evaluate the utility of OPN as a diagnostic biomarker in MS through systematic review of the literature and meta-analysis, and to assess the OPN potential aiding in NTZ treatment evaluation. The gene discussed is SPP1; the disease is myeloid sarcoma.